1[1]Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000[J]. CA Cancer J Clin, 2000, 50(1): 7-33.
2[2]Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial[J]. Lancet, 1998, 352(9122): 98-101.
3[3]Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials[J]. Lancet, 1998, 351(9114): 1451-1467.
4[4]Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually[J]. J Natl Cancer Inst, 1989, 81(24): 1879-1886.
5[5]Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study[J]. J Natl Cancer Inst, 1998, 90(18): 1371-1388.
6[6]Levine M, Moutquin JM, Walton R, et al. Chemoprevention of breast cancer[J]. CMAJ, 2001, 164(12): 1681-1690.
7[7]Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women[J]. Lancet, 1998, 352(9122): 93-97.
8[8]Fisher ER, Fisher B. Relation of a recurrent intraductal carcinoma (ductal carcinoma in situ) to the primary tumor[J]. J Natl Cancer Inst, 2000, 92(4): 288-289.
9[9]Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17[J]. J Clin Oncol, 1998,16(2): 441-452.
10[10]Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial[J]. Lancet, 1999, 353(9169): 1993-2000.
